Exercise intervention attenuates emotional distress and natural killer cell decrements following notification of positive serologic status for HIV-1.

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Exercise intervention attenuates emotional distress and natural killer cell decrements following notification of positive serologic status for HIV-1.

Biofeedback Self Regul. 1990 Sep;15(3):229-42. Unique Identifier : AIDSLINE MED/91027946
LaPerriere AR; Antoni MH; Schneiderman N; Ironson G; Klimas N; Caralis P; Fletcher MA; Center for the Biopsychosocial Studies of AIDS, University of; Miami, Florida.

Abstract: The impact of aerobic exercise training as a buffer of the affective distress and immune decrements which accompany the notification of HIV-1 antibody status in an AIDS risk group was studied. Fifty asymptomatic gay males with a pretraining fitness level of average or below (determined by predicted VO2 max) were randomly assigned to either an aerobic exercise training program or a no-contact control condition. After five weeks of training, at a point 72 hours before serostatus notification, psychometric, fitness and immunologic data were collected on all subjects. Psychometric and immunologic measures were again collected one-week postnotification. Seropositive controls showed significant increases in anxiety and depression, as well as decrements in natural killer cell number following notification whereas, seropositive exercisers showed no similar changes and in fact, resembled both seronegative groups. These findings suggest that concurrent changes in some affective and immunologic measures in response to an acute stressor might be attenuated by an experimentally manipulated aerobic exercise training intervention.

Keywords: Adult Analysis of Variance *Exercise *Homosexuality Human HIV Seropositivity/IMMUNOLOGY/*PSYCHOLOGY Killer Cells, Natural/IMMUNOLOGY Life Style Male Random Allocation Stress, Psychological Support, U.S. Gov't, P.H.S. CLINICAL TRIAL JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIAL
910228
M9120669

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .